Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor

The inhibition of the androgen receptor (AR) is an established strategy in prostate cancer (PCa) treatment until drug resistance develops either through mutations in the ligand-binding domain (LBD) portion of the receptor or its deletion. We previously identified a druggable pocket on the DNA bindin...

Descripción completa

Detalles Bibliográficos
Autores principales: Radaeva, Mariia, Ban, Fuqiang, Zhang, Fan, LeBlanc, Eric, Lallous, Nada, Rennie, Paul S., Gleave, Martin E., Cherkasov, Artem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958344/
https://www.ncbi.nlm.nih.gov/pubmed/33801338
http://dx.doi.org/10.3390/ijms22052493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958344/
https://www.ncbi.nlm.nih.gov/pubmed/33801338
http://dx.doi.org/10.3390/ijms22052493

Ejemplares similares